Drug Information

Drug General Information
Drug ID
D0WL5V
Former ID
DNC007125
Drug Name
LAROPIPRANT
Drug Type
Small molecular drug
Indication Discovery agent Phase 4 [523049], [540312]
Structure
Download
2D MOL

3D MOL
Formula
C21H19ClFNO4S
InChI
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
InChIKey
NXFFJDQHYLNEJK-CYBMUJFWSA-N
CAS Number
CAS 571170-77-9
PubChem Compound ID
9867642
PubChem Substance ID
14832522, 16319858, 24159188, 45289906, 79316133, 96025623, 103506442, 104083674, 125240979, 126671694, 126731356, 134339127, 134344330, 135195695, 136367874, 137185589, 139755590, 144116232, 152255074, 152258799, 152344287, 160647650, 162012049, 162205095, 163125572, 164023436, 172087022, 175266118, 178100382, 186014491, 204366771, 223398991, 223556714, 223674460, 225130865, 227246809, 247021101, 249816641, 251971100, 252451672
Target and Pathway
Target(s) Thromboxane A2 receptor Target Info Inhibitor [528672]
Prostaglandin D2 receptor Target Info Inhibitor [528672]
Prostaglandin E2 receptor, EP1 subtype Target Info Inhibitor [528672]
Prostacyclin receptor Target Info Inhibitor [528672]
Putative G-protein coupled receptor 44 Target Info Inhibitor [528672]
Prostaglandin F2-alpha receptor Target Info Inhibitor [528672]
Prostaglandin E2receptor, EP2 subtype Target Info Inhibitor [528672]
Prostaglandin E2 receptor EP3 subtype Target Info Inhibitor [528672]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Platelet activationhsa04080:Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction
Vascular smooth muscle contraction
Platelet activationhsa04020:Calcium signaling pathway
Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway
Inflammatory mediator regulation of TRP channels
Renin secretion
Pathways in cancerhsa04020:Calcium signaling pathway
cAMP signaling pathway
Regulation of lipolysis in adipocytes
Pathways in cancer
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway PI3 kinase pathway
Pathway Interaction Database Thromboxane A2 receptor signalingtxa2pathway:Thromboxane A2 receptor signaling
PathWhiz Pathway Intracellular Signalling Through PGD2 receptor and Prostaglandin D2PW000452:Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin
Reactome Prostanoid ligand receptors
G alpha (q) signalling events
G alpha (12/13) signalling events
Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors
G alpha (s) signalling eventsR-HSA-391908:Prostanoid ligand receptors
G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors
G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
Signal amplification
GPCR ligand binding
GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation
Endothelin Pathways
Platelet homeostasis
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
GPCR downstream signaling
GPCRs, OtherWP98:Prostaglandin Synthesis and Regulation
Ovarian Infertility Genes
References
Ref 523049ClinicalTrials.gov (NCT01126073) Niacin/Laropiprant and Endothelial Function. U.S. National Institutes of Health.
Ref 540312(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3356).
Ref 528672J Med Chem. 2007 Feb 22;50(4):794-806.Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.